Inclusion Criteria:
  -  Participants were eligible for inclusion in the study if they had evidence suggesting acute ischemic stroke that lasted for â‰¤ 4.5 hours .
  -  Those Participants were treated with intravenous thrombolytic therapy ((recombinant tissue plasminogen activator (rt-PA)).
Exclusion Criteria:
  -  Those who had hemorrhagic stroke
  -  participants presented with acute myocardial infarction, cerebrovascular stroke in the previous three months.
  -  serious head trauma in the previous three months.
  -  urinary tract, lung, or gastrointestinal hemorrhage within the three weeks.
  -  serious trauma or major surgery within the previous two weeks.
  -  lumbar or arterial puncture at a non-compressible site within one week.
  -  those received heparin within 48 hours, resulting in an activated partial thromboplastin time greater than the upper limit of normal.
  -  systolic pressure > 185 mmHg or diastolic pressure > 110 mmHg.
  -  blood glucose <50 or > 400 mg/dL.
  -  current use of anticoagulants with an International Normalized Ratio > 1.7 or prothrombin time>15 sec; platelet count < 100,000/mm3.
  -  pregnancy; serious heart, lung, kidney or other organ dysfunction.
  -  allergy to active ingredients of rt-PA; patients with > 4.5 hours from the last time known to be asymptomatic.
  -  those in whom troponin was not measured at admission were excluded from the study